|
FY2025
12 months to Dec 31, 2025
|
FY2024
12 months to Dec 31, 2024
|
|
|---|---|---|
| Cash flows from operating activities | ||
| Net loss | ||
| Adjustments to reconcile net loss to net cash used by operating activities: | ||
| Amortization of intangibles assets | ||
| Depreciation | ||
| Stock-based compensation expense | ||
| Deferred income taxes | ||
| Amortization of discount on marketable securities | ||
| Goodwill and intangible assets impairment | ||
| Credit loss expense | ||
| Cash payment for equity awards | ||
| Other | ||
| Changes in operating assets and liabilities: | ||
| Accounts receivable | ||
| Supplies | ||
| Operating lease right-of-use assets and liabilities, net | ||
| Prepaid expenses and other assets | ||
| Accounts payable | ||
| Accrued and other liabilities | ||
| Net cash used by operating activities | ||
| Cash flows from investing activities | ||
| Purchases of property and equipment | ||
| Purchases of marketable securities | ||
| Proceeds from maturities of marketable securities | ||
| Net cash used in investing activities | ||
| Cash flows from financing activities | ||
| Proceeds from issuance of common stock | ||
| Private Placement | ||
| At the Market Offering | ||
| Issuance of common stock under ESPP | ||
| Cash funding received from Illumina | ||
| Other | ||
| Net cash provided by financing activities | ||
| Effect of exchange rate changes on cash, cash equivalents, and restricted cash | ||
| Net increase (decrease) in cash, cash equivalents, and restricted cash | ||
| Cash, cash equivalents and restricted cash — beginning of period | ||
| Cash, cash equivalents and restricted cash — end of period | ||
| Supplemental cash flow information: | ||
| Property and equipment included in accounts payable and accrued liabilities | ||
| Operating cash flows from operating leases, net | ||
| Represented by: | ||
| Cash and cash equivalents | ||
| Restricted cash |
Loading...
